Brief: Dynavax Presents Positive Topline Data From Part 1 Of Phase 1/2 Trial For Shingles Vaccine Candidate At Idweek 2025 And Announces Initiation Of Part 2 Of Trial
21/10/2025 21:40
Oct 21 (Reuters) - Dynavax Technologies Corp DVAX.O: DYNAVAX PRESENTS POSITIVE TOPLINE DATA FROM PART 1 OF PHASE 1/2 TRIAL FOR SHINGLES VACCINE CANDIDATE AT IDWEEK 2025 AND ANNOUNCES INITIATION OF PART 2 OF TRIAL DYNAVAX TECHNOLOGIES CORP - Z-1018 SHOWS COMPARABLE RESPONSES TO SHINGRIX WITH FAVORABLE TOLERABILITY DYNAVAX TECHNOLOGIES CORP - INITIATES PART 2 OF TRIAL VERSUS SHINGRIX IN ADULTS 70+ DYNAVAX TECHNOLOGIES CORP - TO REPORT PART 2 DATA IN SECOND HALF OF 2026 Source text: ID:nPn5wBzmNa Further company coverage: DVAX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dynavax Technologies
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
OneSpaWorld jumps as co poised to join S&P SmallCap index
Sanofi targets high single digit sales growth in 2026, plans share buyback (updated)
Focus: Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality